Trodelvy (sacituzumab govitecan-hziy)

Sacituzumab Govitecan Wins Approval in Europe for Pretreated HR+/HER2– Metastatic Breast Cancer @JavierCortesMD @EU_Commission #bcsm https://t.co/3R7Nhoz78m (@OncLive)

Enfortumab vedotin and sacituzumab govitecan, two antibody drug conjugates (ADCs), have shown promising results in treating urothelial cancer. They have exhibited significant objective response rates and durable responses, particularly in patients who have previously received… https://t.co/gwK2m0W2M9 (@nataliagandur)

Exciting developments in urothelial cancer treatment! Enfortumab vedotin, sacituzumab govitecan, and derazantinib are showing promise. Looking forward to EV and pembrolizumab results in first-line and MIBC. SG vs. chemo in platinum refractory disease is generating buzz.… https://t.co/XrJPm7T3jG (@nataliagandur)

Last #ACSCancerChat question @drfrankiejs @tompowles1 & Dr. Young 🙏 What promising results have we seen with antibody drug conjugates🧪in the treatment of urothelial cancer, specifically enfortumab vedotin and sacituzumab govitecan❓ @OncoAlert 🚨 @VivekSubbiah @WalterStadler5 (@weoncologists)

@PBarataMD, MSc, of @TulaneMedicine discussed when to use sacituzumab govitecan for patients with metastatic urothelial cancer. READ MORE: https://t.co/TLQ5Ynezhg (@TargetedOnc)

Not looking: 1A Sacituzumab govitecan = Trop2, br ca 2D Tebentafusp = Gp100, uveal melanoma (w/ HLA serotype selection) 3C Mirvetuximab sorvtansine-gyn = Folate receptor alph ov ca (Guess: gyn = ov ca?) 4B Enfortumab vedotin-ejfv = Nectin-4 bladder/urinary tract ca These are fun (@CDebyaniPhD)

3/15 #TumorBoardTuesday #BCSM 👨🏽‍🏫Mini tweetorial 1 👩🏼‍🏫 📌Sacituzumab govitecan (SG) = antibody drug conjugate (ADC) 🔹ADCs deliver high levels 💪🏾 of chemo to cells with target 🎯 antigen 🔹SG targets Trop2 (cell signaling protein ⬆️ in many solid tumors) (@ArielleMedford)

4/15 #TumorBoardTuesday #BreastCancer 👨🏽‍🏫Mini tweetorial 2👩🏼‍🏫 📌Sacituzumab govitecan (SG) 🔹approved by the @US_FDA for >2L in metastatic TNBC in 2020 based on landmark ASCENT trial ‼️‼️Approval does 🙅🏼‍♀️ NOT require testing for Trop2‼️‼️ 📚#SaraHurvitz https://t.co/J2nIIy2oeg (@ArielleMedford)

5/15 #TumorBoardTuesday 👨🏽‍🏫Mini tweetorial 3👩🏼‍🏫 📌Sacituzumab govitecan (SG) 🔹first ADC approved for use in TNBC! 🫧2022: ADC T-DXd approved for HER2-low BC, including TNBC ⚠️Currently, SG approved ONLY in metastatic BC 👨🏽‍🔬Ongoing studies evaluating in localized TNBC (NeoSTAR🌟) (@ArielleMedford)

Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in pts w/ pretreated, endocrine-resistant, HR+/HER2– metastatic breast cancer. @stolaney1 @DanaFarber #ASCO23 #bcsm https://t.co/FXPBfKcAC4 (@OncLive)

Antibody drug conjugates, including enfortumab vedotin and sacituzumab govitecan, have continued to show activity in urothelial cancer with promising clinical outcomes. 🔗 https://t.co/WWL08K5gL0 @drfrankiejs @tompowles1 @ChrisSweens1 (@JournalCancer)

The EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion regarding sacituzumab govitecan monotherapy in select patients with unresectable or metastatic HR–positive, HER2-negative breast cancer. @JavierCortesMD #bcsm https://t.co/jU6u7chlOD (@OncLive)

Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in pts w/ pretreated, endocrine-resistant, HR+/HER2– metastatic breast cancer. @stolaney1 @DanaFarber #ASCO23 #bcsm https://t.co/iqEOwrj4W5 (@OncLive)

Elizabeth A. Mittendorf, MD, PhD, discussed the TROPiCS-02 trial, which evaluated sacituzumab govitecan in HR–positive, HER2-negative breast cancer. #bcsm | @EMittendorfMD @DanaFarber https://t.co/KFZ6dleKn1 (@TargetedOnc)

Single-agent sacituzumab govitecan has received a positive opinion from @EMA_News regarding its use in unresectable or metastatic HR–positive, HER2-negative breast cancer based on data from the phase 3 TROPiCS-02 study. @JavierCortesMD #bcsm https://t.co/urqbkNoe0v (@OncLive)

My mom is currently fighting mTNBC. She was previously on Trodelvy and most recently Eribulin. Her Oncologist stopped treatment this past week. Are their any other options for her that you could recommend we maybe explore? (@BladeRunnerOO8)

Sacituzumab Govitecan Approaches EU Approval for Pretreated HR+ Metastatic Breast Cancer @JavierCortesMD #bcsm https://t.co/o33ZSKQ21G (@OncLive)

Check out this article with Pedro C. @PBarataMD MD, MSc, as he discusses data supporting the use of sacituzumab govitecan in advanced urothelial carcinoma. #blcsm https://t.co/3ls2HpHQpz (@TargetedOnc)

Check out Dr. Sara Tolaney @stolaney1 @DFCI_BreastOnc discussing #ASCO23 ASCENT-05/OptimICE-RD (AFT-65): Adj. Sacituzumab Govitecan + Pembro vs Pembro ± Capecitabine in TNBC and Residual Disease After Neoadj. Therapy and Surgery #bcsm #TNBC #breastcancer https://t.co/3b91SEY9Xu (@Sameh_VuMedi)

This is exciting news for the urothelial cancer community. The efficacy of sacituzumab govitecan in treating locally advanced or metastatic cancer by targeting Trop-2 expression is promising. Thank you for sharing this research, @DrScottTagawa. (@itziarlarrodele)

.@stolaney1 reviewed how findings from the phase 3 TROPiCS-02 study highlight the ability of sacituzumab govitecan to improve patient outcomes over chemotherapy among those with HR+, HER2- metastatic breast cancer. #bcsm #ASCO23 | @ASCO @DanaFarber https://t.co/upHPLvtAUe (@CancerNetwrk)

Check out Dr. Sara Tolaney @stolaney1 @DFCI_BreastOnc discussing #ASCO23 TROPiCS-02 Phase 3 Study Final OS Analysis - Sacituzumab Govitecan in Pts With HR+/HER2- #mBC #bcsm #OncTwitter #OncEd #breastcancer #Biomarkers #PrecisionOncology https://t.co/giGo9yPxs5 (@Sameh_VuMedi)

🔘 #ASCO23 - Efficacy of Sacituzumab Govitecan in Locally Advanced or Metastatic Urothelial Cancer by Trophoblast Cell Surface Antigen 2 (Trop-2) Expression #bladdercancer @urotoday https://t.co/Db70Bui11U (@drenriquegrande)

Sara Tolaney, MD, MPH, discusses sacituzumab govitecan for patients with HR+/HER2- metastatic #breastcancer based on data from the TROPiCS-02 study. #bcsm #ASCO2023 | @DanaFarber @stolaney1 @ASCO https://t.co/oNdgIgDFxn (@TargetedOnc)

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer @stolaney1 @DanaFarber @ASCO #ASCO23 #bcsm #oncology https://t.co/GmsaUYYiOR (@OncLive)

Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). @stolaney1 Summary: https://t.co/EhtJ4vYzX0 #ASCO23 #bcsm (@paspears88)

Biomarkers of response to sacituzumab govitecan and efficacy after treatment with enfortumab vedotin in advanced #UrothelialCarcinoma: analysis of the #UNITE study. Presented by @Tanjin097 @UCSFCancer. #ASCO23 coverage by @tchandra_uromd @UCDavisUrology > https://t.co/oc73iN3EDJ (@urotoday)

Efficacy of sacituzumab govitecan in locally advanced or metastatic #UrothelialCancer by trophoblast cell surface antigen 2 (Trop-2) expression. Presentation by @DrScottTagawa @WeillCornell. #ASCO23 written coverage by @tchandra_uromd @UCDavisUrology > https://t.co/07sVljr7Ln (@urotoday)

TROPiCS-02: sacituzumab govitecan vs TPC in HR+/HER2- MBC Median follow-up 12.8 mo PFS 5.5 vs 4.0 mo, HR 0.65 OS (exploratory) 14.5 vs 11.2 mo, HR 0.79 Less benefit if no visceral mets, but small subgroup. ORR 21% vs 14% @stolaney1 @DanaFarber @DFCI_BreastOnc #ASCO23 #bcsm (@MVanMeterMD)

#ASCO23 #BreastCancer Poster Session: ASCENT-05/OptimICE-RD: Phase 3 study of adjuvant sacituzumab govitecan + pembro vs pembro ± capecitabine in patients with #TNBC and residual disease after neoadjuvant therapy and surgery. @stolaney1 @DrLisaCarey https://t.co/TrKYcAAzD6 (@DFCI_BreastOnc)

🎥We spoke with @stolaney1 of @DanaFarber at #ASCO23 on TROPiCS-02 assessing sacituzumab govitecan inHR+/HER- #BreastCancer: ➡️https://t.co/6TSA6ufXKA 👀Final OS analysis to be presented tomorrow here at #ASCO23 - watch this space for the full interview! @ASCO #BCSM (@VJOncology)

The formidable @AndreaNecchi discussing variant histos & biomarkers for pembro benefit in #bladdercancer and no need for genotype selection before #sacituzumabgovitecan treatment @asco #ASCO23 @oncoalert (@TiansterZhang)

Ab#4579 #ASCO23 @ASCO : The efficacy of sacituzumab govitecan (SG) in locally advanced /mUC #bladdercancer by TROP-2 expression➡️similar ORR, outcomes in high and low tumor Trop-2 expression➡️SG activity independent of Trop-2 expression in UC👉https://t.co/iHVesazJi7 Congrats… https://t.co/GovZiufMFI (@neerajaiims)

Was just about to share the stellar work by rising star @TalalZarif1. @DrChoueiri “The approval of sacituzumab govitecan further increases the complexity of sequencing agents for FGFR2/3 altered patients” #bladdercancer (@MarounBouZerdan)

ICYMI: @stolaney1, of @DanaFarber, discusses sacituzumab govitecan in patients with unresectable locally advanced or metastatic HR+, HER2– breast cancer & how this agent can fulfill unmet needs for this patient population in this episode of #OncLiveOnAir. https://t.co/xWPT3RC99d (@OncLive)

In this episode of #OncLiveOnAir, @stolaney1, of @DanaFarber, discusses the FDA approval of sacituzumab govitecan in unresectable locally advanced or metastatic HR+/HER2– #bcsm, & how this agent can fulfill unmet needs for this patient population. https://t.co/dywVjY1L2f (@OncLive)

New @OncLive On Air podcast featuring Dr. Tolaney (@stolaney1) discussing the FDA approval of sacituzumab govitecan in unresectable locally advanced or metastatic HR+/HER2– #breastcancer. Listen here▶️ https://t.co/nWs16lTaM0 (@DFCI_BreastOnc)

In this episode of #OncLiveOnAir, @stolaney1, of @DanaFarber, discusses the FDA approval of sacituzumab govitecan in unresectable locally advanced or metastatic HR+/HER2– #bcsm, & how this agent can fulfill unmet needs for this patient population. https://t.co/NsCuRzUPNk (@OncLive)

#TNBC experts: when PD-L1 neg, Her2:0 dz progresses on or immediately after Keynote 522 and on Trodelvy where do u go? #bcsm (@Dr_RShatsky)

FDA Approves Sacituzumab Govitecan-hziy for HR+/HER2- Metastatic Breast Cancer https://t.co/lYUt8Muhzd @dipeshuprety4 (@BTFCancerNews)

#ICYMI: Patients with pre-treated, unresectable locally advanced or metastatic HR+, HER2-negative breast cancer can now receive treatment with sacituzumab govitecan following approval from the FDA. #bcsm | @US_FDA @FDAOncology @stolaney1 https://t.co/q1BN71Kkrm (@CancerNetwrk)

Breaking. #FDA Approves #Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer https://t.co/n92W9qaVDU via @onclive (@a_nourallah)